Tafenoquine

Tafenoquine
Clinical data
Pronunciationta fen' oh kwin
Trade namesKrintafel, Arakoda, others
Other namesEtaquine, WR 238605, SB-252263
AHFS/Drugs.comMonograph
MedlinePlusa618050
License data
Pregnancy
category
  • AU: C
Routes of
administration
By mouth
Drug classAntimalarial
ATC code
Legal status
Legal status
Identifiers
  • N-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H28F3N3O3
Molar mass463.501 g·mol−1
3D model (JSmol)
  • FC(F)(F)c3cc(Oc1c(OC)cc(NC(C)CCCN)c2nc(OC)cc(c12)C)ccc3
  • InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3 Y
  • Key:LBHLFPGPEGDCJG-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Tafenoquine, sold under the brand name Krintafel among others, is a medication used to prevent and to treat malaria. With respect to acute malaria, it is used together with other medications to prevent relapse by Plasmodium vivax. It may be used to prevent all types of malaria. It is taken by mouth.

Common side effects include vomiting, headache, and dizziness. Other side effects may include methemoglobinemia, trouble sleeping, and anaphylaxis. In people with G6PD deficiency, red blood cell breakdown may occur. Use in pregnancy is not recommended. Tafenoquine is in the 8-aminoquinoline family of medications. The mechanism of action is unclear but it is effective both in the liver and bloodstream. A possible mechanism of action and other novel perspectives have been published.

Tafenoquine was approved for medical use in Australia and in the United States in 2018. Tafenoquine is related to primaquine.